ABIO ARCA biopharma Inc.

+0.09  (+2%)
Previous Close 5.55
Open 5.61
Price To Book 0.9
Market Cap 8,209,336
Shares 1,455,556
Volume 231,079
Short Ratio
Av. Daily Volume 84,526

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1Q 2020 subject to financing. Interim data 3Q 2021; topline data: 2Q 2022.
Chronic Heart Failure

Latest News

  1. ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
  2. One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price
  3. ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
  4. ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update
  5. GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
  6. ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial
  7. Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
  8. Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
  9. ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
  10. ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
  11. Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
  12. ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling
  13. ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
  14. ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  15. GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
  16. ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
  17. Westminster biotech company receives second extension on delisting notice from Nasdaq
  18. Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics